Together, these findings demonstrate MYCN-dependent effects of TrkC signalling and highlight the therapeutic potential of targeting the PKA pathway to induce differentiation in high-risk MYCN-amplified neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.